Cardiac hypertrophy is the main risk factor for congestive heart failure, which is the end-stage condition of a number of cardiac disorders. Deregulation of redox homeostasis in the heart has been implicated in the development of cardiac hypertrophy and heart failure. Recent studies suggest that PPARgamma may exert anti-hypertrophic effects with unknown mechanism(s). Our preliminary studies revealed that mice with - cardiomyocyte-restricted PPARgamma deficiency showed substantially increased superoxide in their heart prior to progressive cardiac hypertrophy and progression to heart failure. We postulate that PPARgamma is an essential determinant of myocardial redox homeostasis via transcriptional regulation of a key endogenous mitochondrial antioxidant, magenese, superoxide dismutase (SOD2), in the heart, thus serving as a pivotal regulator for the heart in response to various pathophysiological conditions. We will use a combination of in vitro, in vivo and ex vivo methods to test our central hypothesis that cardiac PPARgamma improves pathological left ventricular hypertrophic responses in cardiomyocytes by activating expression of SOD2 to diminish harmful superoxide in cardiomyocytes. Specifically, we will achieve the following specific aims:
aim 1, to determine how PPARgamma regulates expression of genes encoding SOD2 in vitro;
aim 2, to determine effects of cardiac PPARgamma on SOD2 expression in mice with either cardiomyocyte-restricted knockout of PPARgamma or overexpression of a constitutively active PPARgamma;
aim 3, to define the role of PPARgamma in the progression from compensated cardiac hypertrophy to heart failure using a targeted inducible cardiomyocyte-restricted PPARgamma knockout mice. We will also determine if SOD2 mimetic drugs ameliorates or prevents further oxidative damage in the cardiomyocyte-restricted PPARgamma knockout mice. We will characterize PPARgamma controlled antioxidant gene expression, cardiac morphology, reactive oxygen species production, cardiac function, myocardial bioenergetics and oxidative damage in the heart of PPARgamma transgenic mice during the development of cardiac hypertrophy and heart failure induced by pressure-overload. Results from these studies should provide novel mechanisms on the regulation of cardiac redox homeostasis and hence provide new insights into novel therapeutic targets for the prevention and treatment of cardiac hypertrophy and heart failure.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL085499-05
Application #
7880923
Study Section
Cardiac Contractility, Hypertrophy, and Failure Study Section (CCHF)
Program Officer
Evans, Frank
Project Start
2006-08-01
Project End
2012-04-30
Budget Start
2010-05-01
Budget End
2012-04-30
Support Year
5
Fiscal Year
2010
Total Cost
$351,988
Indirect Cost
Name
University of Alabama Birmingham
Department
Nutrition
Type
Schools of Allied Health Profes
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Ding, Yishu; Yang, Kevin D; Yang, Qinglin (2014) The role of PPAR? signaling in the cardiovascular system. Prog Mol Biol Transl Sci 121:451-73
Jiang, Ding-Sheng; Bian, Zhou-Yan; Zhang, Yan et al. (2013) Role of interferon regulatory factor 4 in the regulation of pathological cardiac hypertrophy. Hypertension 61:1193-202
Wang, Xin-An; Zhang, Ran; Jiang, Dingsheng et al. (2013) Interferon regulatory factor 9 protects against hepatic insulin resistance and steatosis in male mice. Hepatology 58:603-16
Kim, Teayoun; Zhelyabovska, Olga; Liu, Jian et al. (2013) Generation of an inducible, cardiomyocyte-specific transgenic mouse model with PPAR ?/? overexpression. Methods Mol Biol 952:57-65
He, Lan; Kim, Teayoun; Long, Qinqiang et al. (2012) Carnitine palmitoyltransferase-1b deficiency aggravates pressure overload-induced cardiac hypertrophy caused by lipotoxicity. Circulation 126:1705-16
Bian, Zhou-Yan; Wei, Xiang; Deng, Shan et al. (2012) Disruption of mindin exacerbates cardiac hypertrophy and fibrosis. J Mol Med (Berl) 90:895-910
Zou, Luyun; Zhu-Mauldin, Xiaoyuan; Marchase, Richard B et al. (2012) Glucose deprivation-induced increase in protein O-GlcNAcylation in cardiomyocytes is calcium-dependent. J Biol Chem 287:34419-31
Yan, Ling; Wei, Xiang; Tang, Qi-Zhu et al. (2011) Cardiac-specific mindin overexpression attenuates cardiac hypertrophy via blocking AKT/GSK3? and TGF-?1-Smad signalling. Cardiovasc Res 92:85-94
Gong, Kaizheng; Chen, Yiu-Fai; Li, Peng et al. (2011) Transforming growth factor-? inhibits myocardial PPAR? expression in pressure overload-induced cardiac fibrosis and remodeling in mice. J Hypertens 29:1810-9
Liu, Jian; Wang, Peiyong; He, Lan et al. (2011) Cardiomyocyte-Restricted Deletion of PPAR?/? in PPAR?-Null Mice Causes Impaired Mitochondrial Biogenesis and Defense, but No Further Depression of Myocardial Fatty Acid Oxidation. PPAR Res 2011:372854

Showing the most recent 10 out of 27 publications